...
【24h】

Update on Lung Cancer Screening

机译:肺癌筛选的更新

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Over the past 10 years, there has been substantial progress in the study and implementation of lung cancer screening using low-dose computed tomography (LDCT). The National Lung Screening Trial, the recently reported NELSON (NEderlands-Leuvens Longkanker Screenings ONderzoek) trial, and other European trials provide strong evidence for the efficacy of LDCT to reduce lung cancer mortality. This has resulted in the United State's Preventative Task Force and numerous professional medical societies adopting lung cancer screening recommendations. Despite the general acceptance of the positive effect of screening, low adoption and implementation rates remain nationally. In this article, the authors discuss the evolution and current state of the evidence for LDCT screening for lung cancer. The authors will also review the associated risks, cost, and challenges of implementation of an LDCT screening program.
机译:在过去的10年里,使用低剂量计算断层扫描(LDCT)研究和实施肺癌筛查的研究和实施是大量进展。 国家肺筛查试验,最近报道的纳尔逊(Nederlands-Leuvens Longkanker Shorting Onderzoek)审判,以及其他欧洲试验为LDCT降低肺癌死亡率的疗效提供了强有力的证据。 这导致了联合国预防性工作队和众多专业医学社团,采用肺癌筛查建议。 尽管普遍接受筛查的积极影响,但低收量和实施率仍然存在全国性。 在本文中,作者讨论了肺癌LDCT筛查证据的演变和现状。 作者还将审查LDCT筛查计划的相关风险,成本和挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号